
---
title: '百奥泰：注射用BAT8008获得临床试验批准通知书'
categories: 
 - 金融
 - 证券时报网
 - 快讯
headimg: 'https://picsum.photos/400/300?random=2910'
author: 证券时报网
comments: false
date: Tue, 23 Aug 2022 17:03:00 GMT
thumbnail: 'https://picsum.photos/400/300?random=2910'
---

<div>   
<p>证券时报e公司讯，<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SS688177" style="color: #2f67d1;text-decoration: none;" code="688177" target="_blank">百奥泰</a>(688177)8月23日晚间公告，注射用BAT8008获得临床试验批准通知书。BAT8008是<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SS688177" style="color: #2f67d1;text-decoration: none;" code="688177" target="_blank">百奥泰</a>开发的靶向Trop2的抗体药物偶联物（ADC），拟开发用于实体肿瘤治疗。</p>

                  
</div>
            